Future viable models of psychiatry drug discovery in pharma

Journal of Biomolecular Screening

Volumn 18, Issue 5, 2013, Pages 509-521

  Rizzo, Stacey J Sukoff ^a   Edgerton, Jeremy R ^a   Hughes, Zoë A ^a   Brandon, Nicholas J ^b  

^a PFIZER INC   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

animal models; drug discovery; psychiatry; screening

Indexed keywords

CANNABINOID; DOPAMINE 2 RECEPTOR; FLUOXETINE; GLYCINE TRANSPORTER 1; HISTONE DEACETYLASE 2; INTERLEUKIN 6; METABOTROPIC RECEPTOR 5; NEUROKININ; SEROTONIN RECEPTOR; SEROTONIN TRANSPORTER;

ALZHEIMER DISEASE; AUTISM; BEHAVIOR CHANGE; CELL PROLIFERATION; COGNITION; CONSTRUCT VALIDITY; CYSTIC FIBROSIS; DRUG DEVELOPMENT; DYSTONIA; ECOSYSTEM; ELECTRIC POTENTIAL; EPILEPSY; EXECUTIVE FUNCTION; GILLES DE LA TOURETTE SYNDROME; HUMAN; HUNTINGTON CHOREA; IN VITRO STUDY; IN VIVO STUDY; MAJOR DEPRESSION; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; OXYGEN CONSUMPTION; PARKINSON DISEASE; PHENOTYPE; PLURIPOTENT STEM CELL; POSITIVE AND NEGATIVE SYNDROME SCALE; PREFRONTAL CORTEX; PRIORITY JOURNAL; PSYCHIATRY; PSYCHOPHARMACOTHERAPY; QUALITY OF LIFE; REVIEW; SCHIZOPHRENIA; TREATMENT RESISTANT DEPRESSION; WORKING MEMORY;

ANIMAL MODELS; DRUG DISCOVERY; PSYCHIATRY; SCREENING;

ANIMALS; ANTIPSYCHOTIC AGENTS; DRUG DISCOVERY; HUMANS; MENTAL DISORDERS; MODELS, ANIMAL; MOLECULAR TARGETED THERAPY;

EID: 84878190712     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057113475871     Document Type: Review

References (79)

1. Preskorn S. H.. CNS Drug Development: Part I: The Early Period of CNS Drugs. Psychopharmacology. J. Psychiatr. Pract. 2010 ; 16: 334-339
2. Schwartz T. L.. Metabolites: Novel Therapeutics or "Me-Too" Drugs? Using Desvenlafaxine as an Example. CNS Spectrums. 2012 ; 17: 103-106
3. Sopko M. A., Ehret M. J., Grgas M.. Desvenlafaxine: Another "Me Too" Drug?. Ann. Pharmacother. 2008 ; 42: 1439-1446
4. Gagny J. J., Choudhry N. K.. How Many "Me-Too" Drugs Is Too Many?. JAMA. 2011 ; 305: 711-712
5. Harrison C.. Patent Watch: The Patent Cliff Steepens. Nat. Rev. Drug Discov. 2011 ; 10: 12-13
6. Hughes J. P., Rees S., Kalindjian S. B., Philpott K. L.. Principles of Early Drug Discovery. Br. J. Pharmacol. 2011 ; 162: 1239-1249
7. Swinney D. C., Anthony J.. How Were New Medicines Discovered?. Nat. Rev. Drug Discov. 2011 ; 10: 507-519
8. Arrowsmith J.. Trial Watch: Phase II Failures: 2008-2010. Nat. Rev. Drug Discov. 2011 ; 10: 328-329
9. Arrowsmith J.. Trial Watch: Phase III and Submission Failures: 2007-2010. Nat. Rev. Drug Discov. 2011 ; 10: 87
10. Hyman S. E.. Revolution Stalled. Sci. Trans. Med. 2012 ; 4: 11
11. Terstappen G. C., Schlüpen C., Raggiaschi R., Gaviraghi G.. Target Deconvolution Strategies in Drug Discovery. Nat. Rev. Drug Discov. 2007 ; 6: 891-903 (Pubitemid 350042397)
12. Holmes D.. Stem Cell Scientists Share 2012 Nobel Prize for Medicine. Lancet. 2012 1295 ; 380 :
13. Grskovic M., Javaherian A., Strulovici B., Daley G. Q.. Induced Pluripotent Stem Cells: Opportunities for Disease Modeling and Drug Discovery. Nat. Rev. Drug Discov. 2011 ; 10: 915-929
14. Israel M. A., Yuan S. H., Bardy C., Reyna S. M., Mu Y., Herrera C., Hefferan M. P., Van Gorp S., Nazor K. L., Boscolo F. S., et al. Probing Sporadic and Familial Alzheimer's Disease Using Induced Pluripotent Stem Cells. Nature. 2012 ; 482: 216-220
15. Brennand K. J., Simone A., Jou J., Gelboin-Burkhart C., Tran N., Sangar S., Li Y., Mu Y., Chen G., Yu D., et al. Modelling Schizophrenia Using Human Induced Pluripotent Stem Cells. Nature. 2012 ; 473: 221-225
16. Devine M. J., Ryten M., Vodicka P., Thomson A. J., Burdon T., Houlden H., Cavaleri F., Nagano M., Drummond N. J., Taanman J. W., et al. Parkinson's Disease Induced Pluripotent Stem Cells with Triplication of the Alpha-Synuclein Locus. Nat. Commun. 2011 ; 2: 440
17. Farra N., Zhang W. B., Pasceri P., Eubanks J. H., Salter M. W., Ellis J.. Rett Syndrome Induced Pluripotent Stem Cell-Derived Neurons Reveal Novel Neurophysiological Alterations. Mol. Psychiatry. 2012 ; 17: 1261-1271
18. Pasca S. P., Portmann T., Voineagu I., Yazawa M., Shcheglovitov A., Paşca A. M., Cord B., Palmer T. D., Chikahisa S., Nishino S., et al. Using iPSC-Derived Neurons to Uncover Cellular Phenotypes Associated with Timothy Syndrome. Nat. Med. 2011 ; 17: 1657-1662
19. Tallman J. F.. Neuropsychopharmacology at the New Millennium: New Industry Directions. Neuropsychopharmacology. 1999 ; 20: 99-105 (Pubitemid 29010369)
20. Markou A., Chiamulera C., Geyer M. A., Tricklebank M., Steckler T.. Removing Obstacles in Neuroscience Drug Discovery: The Future Path for Animal Models. Neuropsychopharmacology. 2009 ; 34: 74-89
21. Cryan J. F., Markou A., Lucki I.. Assessing Antidepressant Activity in Rodents: Recent Developments and Future Needs. Trends Pharmacol. Sci. 2002 ; 23: 238-245 (Pubitemid 34465544)
22. Castagne V., Moser P. C., Porsolt R. D.. Preclinical Behavioral Models for Predicting Antipsychotic Activity. Adv. Pharmacol. 2009 ; 57: 381-418
23. Porsolt R. D., Moser P. C., Castagne V.. Behavioral Indices in Antipsychotic Drug Discovery. J. Pharmacol. Exp. Ther. 2010 ; 333: 632-638
24. Pratt J., Winchester C., Dawson N., Morris B.. Advancing Schizophrenia Drug Discovery: Optimizing Rodent Models to Bridge the Translational Gap. Nat. Rev. Drug Discov. 2012 ; 211: 560-579
25. Jones C. A., Watson D. J., Fone K. C.. Animal Models of Schizophrenia. Br. J. Pharmacol. 2011 ; 164: 1162-1194
26. Hradetzky E., Sanderson T. M., Tsang T. M., Sherwood J. L., Fitzjohn S. M., Lakics V., Malik N., Schoeffmann S., O'Neill M. J., Cheng T. M., et al. The Methylazoxymethanol Acetate (MAM-E17) Rat Model: Molecular and Functional Effects in the Hippocampus. Neuropsychopharmacology. 2011 ; 37: 364-377
27. Karayiorgou M., Simon T. J., Gogos J. A.. 22q11.2 Microdeletions: Linking DNA Structural Variation to Brain Dysfunction and Schizophrenia. Nat. Rev. Neurosci. 2010 ; 11: 402-416
28. Paylor R., McIlwain K. L., McAninch R., Nellis A., Yuva-Paylor L. A., Baldini A., Lindsay E. A.. Mice Deleted for the DiGeorge/Velocardiofacial Syndrome Region Show Abnormal Sensorimotor Gating and Learning and Memory Impairments. Hum. Mol. Genet. 2001 ; 10: 2645-2650 (Pubitemid 33133405)
29. Mukai J., Dhilla A., Drew L. J., Stark K. L., Cao L., MacDermott A. B., Karayiorgou M., Gogos J. A.. Palmitoylation-Dependent Neurodevelopmental Deficits in a Mouse Model of 22q11 Microdeletion. Nat. Neurosci. 2008 ; 11: 1302-1310
30. St Clair D., Blackwood D., Muir W., Carothers A., Walker M., Spowart G., Gosden C., Evans H. J.. Association within a Family of a Balanced Autosomal Translocation with Major Mental Illness. Lancet. 1990 ; 336: 13-16 (Pubitemid 20207869)
31. Brandon N. J., Sawa A.. Linking Neurodevelopmental and Synaptic Theories of Mental Illness through DISC1. Nat. Rev. Neurosci. 2011 ; 12: 707-722
32. Moore H., Jentsch J. D., Ghajarnia M., Geyer M. A., Grace A. A.. A Neurobehavioral Systems Analysis of Adult Rats Exposed to Methylazoxymethanol Acetate on E17: Implications for the Neuropathology of Schizophrenia. Biol. Psychiatry. 2006 ; 60: 253-264 (Pubitemid 44093447)
33. Sukoff Rizzo S. J., Neal S. J., Hughes Z. A., Beyna M., Rosenzweig-Lipson S., Moss S. J., Brandon N. J.. Evidence for Sustained Elevation of IL-6 in the CNS as a Key Contributor of Depressive Like Phenotypes. Transl. Psychiatry. 2012 ; 2: e199
34. Maeng S., Zarate C.A., Du J., Schloesser R. J., McCammon J., Chen G., Manji H. K.. Cellular Mechanisms Underlying the Antidepressant Effects of Ketamine: Role of Alpha-Amino-3-Hydroxy-5-Methylisoxazole-4-Propionic Acid Receptors. Biol. Psychiatry. 2008 ; 63: 349-352 (Pubitemid 351146651)
35. Yilmaz A., Schulz D., Aksoy A., Canbeyli R.. Prolonged Effect of an Anesthetic Dose of Ketamine on Behavioral Despair. Pharmacol. Biochem. Behav. 2002 ; 71: 341-344
36. Popik P., Kos T., Sowa-Kućma M., Nowak G.. Lack of Persistent Effects of Ketamine in Rodent Models of Depression. Psychopharmacology (Berl). 2008 ; 198: 421-430
37. Patil S. T., Zhang L., Martenyi F., Lowe S. L., Jackson K. A., Andreev B. V., Avedisova A. S., Bardenstein L. M., Gurovich I. Y., Morozova M. A., et al. Activation of mGlu2/3 Receptors as a New Approach to Treat Schizophrenia: A Randomized Phase 2 Clinical Trial. Nat. Med. 2007 ; 13: 1102-1107 (Pubitemid 47517511)
38. Eli Lilly and Company. LY-2140023 (pomaglumetad methionil) (1R,4S,5S,6S)-4-[[(2S)-2-Amino-4-(methylthio)-1-oxobutyl]amino]-2-thiabicyclo[3. 1.0]hexane-4,6-dicarboxylic Acid 2,2-Dioxide. https://investor.lilly.com/ releasedetail.cfm?ReleaseID=703018. August29, 2012. Accessed December 10, 2012.
39. Kurita M., Holloway T., García-Bea A., Kozlenkov A., Friedman A. K., Moreno J. L., Heshmati M., Golden S. A., Kennedy P. J., Takahashi N., et al. HDAC2 Regulates Atypical Antipsychotic Responses through the Modulation of mGlu2 Promoter Activity. Nat. Neurosci. 2012 ; 15: 1245-1254
40. Grimwood S., Hartig P. R.. Target Site Occupancy: Emerging Generalizations from Clinical and Preclinical Studies. Pharmacol. Ther. 2009 ; 122: 281-301
41. Jones T., Rabiner E. A.. The Development, Past Achievements, and Future Directions of Brain PET. J. Cereb. Blood Flow Metab. 2012 ; 32: 1426-1454
42. Hows M. E., Lacroix L., Heidbreder C., Organ A. J., Shah A. J.. High-Performance Liquid Chromatography/Tandem Mass Spectrometric Assay for the Simultaneous Measurement of Dopamine, Norepinephrine, 5-Hydroxytryptamine and Cocaine in Biological Samples. J. Neurosci. Methods. 2004 ; 138: 123-132 (Pubitemid 39485985)
43. Morgan P., Van Der Graaf P. H., Arrowsmith J., Feltner D. E., Drummond K. S., Wegner C. D., Street S. D. A.. Can the Flow of Medicines Be Improved? Fundamental Pharmacokinetic and Pharmacological Principles toward Improving Phase II Survival. Drug Discov. Today. 2012 ; 17: 419-424
44. Remington G., Kapur S.. Antipsychotic Dosing: How Much but Also How Often?. Schizophr. Bull. 2010 ; 36: 900-903
45. Samaha A. N., Reckless G. E., Seeman P., Diwan M., Nobrega J. N., Kapur S. S.. Less Is More: Antipsychotic Drug Effects Are Greater with Transient Rather Than Continuous Delivery. Biol. Psychiatry. 2008 ; 64: 145-152
46. Castner S. A., Smagin G. N., Piser T. M., Wang Y., Smith J. S., Christian E. P., Mrzljak L., Williams G. V.. Immediate and Sustained Improvements in Working Memory after Selective Stimulation of Alpha7 Nicotinic Acetylcholine Receptors. Biol. Psychiatry. 2011 ; 69: 12-18
47. EnVivo Pharmaceuticals. EVP-6124 (R)-7-chloro-N-quinuclidin-3-yl)benzo[b] thiophene-2-carboxamide. http://www.envivopharma.com/news-item.php?id=35. December5, 2011. Accessed December 10, 2012.
48. Cools R., D'Esposito M.. Inverted-U-Shaped Dopamine Actions on Human Working Memory and Cognitive Control. Biol. Psychiatry. 2011 ; 69: e113 - e125
49. Mullard A.. Reliability of 'New Drug Target' Claims Called into Question. Nat. Rev. Drug Discov. 2011 ; 10: 643-644
50. Prinz F., Schlange T., Asadullah K.. Believe It or Not: How Much Can We Rely on Published Data on Potential Drug Targets?. Nat. Rev. Drug Discov. 2011 ; 10: 712
51. van der Staay F. J., Arndt S. S., Nordquist R. E.. Evaluation of Animal Models of Neurobehavioral Disorders. Behav. Brain Funct. 2009 ; 5: 11
52. O'Hara B.. Negative Results Are Published. Nature. 2011 ; 471: 448-449
53. Carli M., Robbins T. W., Evenden J. L., Everitt B. J.. Effects of Lesions to Ascending Noradrenergic Neurones on Performance of a 5-Choice Serial Reaction Task in Rats; Implications for Theories of Dorsal Noradrenergic Bundle Function Based on Selective Attention and Arousal. Behav. Brain Res. 1983 ; 9: 361-380 (Pubitemid 13002330)
54. Barry R. J., Clarke A. R., Hajos M., McCarthy R., Selikowitz M., Bruggemann J. M.. Acute Atomoxetine Effects on the EEG of Children with Attention-Deficit/Hyperactivity Disorder. Neuropharmacology. 2009 ; 57: 702-707
55. Braff D. L., Geyer M. A., Swerdlow N. R.. Human Studies of Prepulse Inhibition of Startle: Normal Subjects, Patient Groups, and Pharmacological Studies. Psychopharmacology (Berl). 2001 ; 156: 234-258 (Pubitemid 32705488)
56. Delong M., Wichmann T.. Deep Brain Stimulation for Movement and Other Neurologic Disorders. Ann. N. Y. Acad. Sci. 2012 ; 1265: 1-8
57. Buzsáki G., Draguhn A.. Neuronal Oscillations in Cortical Networks. Science. 2004 ; 304: 1926-1929
58. Fries P.. Neuronal Gamma-Band Synchronization as a Fundamental Process in Cortical Computation. Annu. Rev. Neurosci. 2009 ; 32: 209-224
59. Uhlhaas P. J., Singer W.. Neural Synchrony in Brain Disorders: Relevance for Cognitive Dysfunctions and Pathophysiology. Neuron. 2006 ; 52: 155-168 (Pubitemid 44466360)
60. Cornew L., Roberts T. P. L., Blaskey L., Edgar J. C.. Resting-State Oscillatory Activity in Autism Spectrum Disorders. J. Autism Dev. Disord. 2012 ; 42: 188418-188494
61. Marco E. J., Hinkley L. B. N., Hill S. S., Nagarajan S. S.. Sensory Processing in Autism: A Review of Neurophysiologic Findings. Pediatr. Res. 2011 ; 69 (Pt. 2). 48R - 54R
62. Linkenkaer-Hansen K., Monto S., Rytsälä H., Suominen K., Isometsä E., Kähkönen S.. Breakdown of Long-Range Temporal Correlations in Theta Oscillations in Patients with Major Depressive Disorder. J. Neurosci. 2005 ; 25: 10131-10137 (Pubitemid 41636209)
63. Jeong J.. EEG Dynamics in Patients with Alzheimer's Disease. Clin. Neurophysiol. 2004 ; 115: 1490-1505 (Pubitemid 38760295)
64. Beste C., Ness V., Falkenstein M., Saft C.. On the Role of Fronto-Striatal Neural Synchronization Processes for Response Inhibition-Evidence from ERP Phase-Synchronization Analyses in Pre-Manifest Huntington's Disease Gene Mutation Carriers. Neuropsychologia. 2011 ; 49: 3484-3493
65. Conner C. R., Ellmore T. M., Pieters T. A., DiSano M. A., Tandon N.. Variability of the Relationship between Electrophysiology and BOLD-fMRI across Cortical Regions in Humans. J. Neurosci. 2011 ; 31: 12855-12865
66. Gray C. M., Singer W.. Stimulus-Specific Neuronal Oscillations in Orientation Columns of Cat Visual Cortex. Proc. Natl. Acad. Sci. U. S. A. 1989 ; 86: 1698-1702 (Pubitemid 19078968)
67. Kwon J. S., O'Donnell B. F., Wallenstein G. V., Greene R. W., Hirayasu Y., Nestor P. G., Hasselmo M. E., Potts G. F., Shenton M. E., McCarley R. W.. Gamma Frequency-Range Abnormalities to Auditory Stimulation in Schizophrenia. Arch. Gen. Psychiatry. 1999 ; 56: 1001-1005 (Pubitemid 29526383)
68. Uhlhaas P. J., Singer W.. Abnormal Neural Oscillations and Synchrony in Schizophrenia. Nat. Rev. Neurosci. 2010 ; 11: 100-113
69. Lewis D., Curley A., Glausier J. R., Volk D. W.. Cortical Parvalbumin Interneurons and Cognitive Dysfunction in Schizophrenia. Trends Neurosci. 2011 ; 35: 57-67
70. Buzsáki G., Anastassiou C. A., Koch C.. The Origin of Extracellular Fields and Currents - EEG, ECoG, LFP and Spikes. Nat. Rev. Neurosci. 2012 ; 13: 407-420
71. Li J., Bravo D. S., Upton A. L., Gilmour G., Tricklebank M. D., Fillenz M., Martin C., Lowry J. P., Bannerman D. M., McHugh S. B.. Close Temporal Coupling of Neuronal Activity and Tissue Oxygen Responses in Rodent Whisker Barrel Cortex. Eur. J. Neurosci. 2011 ; 34: 1983-1996
72. Francois J., Conway M. W., Lowry J. P., Tricklebank M. D., Gilmour G.. Changes in Reward-Related Signals in the Rat Nucleus Accumbens Measured by In Vivo Oxygen Amperometry Are Consistent with fMRI BOLD Responses in Man. NeuroImage. 2012 ; 60: 2169-2181
73. Ginovart N., Wilson A. A., Meyer J. H., Hussey D., Houle S.. Positron Emission Tomography Quantification of [11C]-DASB Binding to the Human Serotonin Transporter: Modeling Strategies. J. Cereb. Blood Flow Metab. 2001 ; 21: 1342-1353 (Pubitemid 33130946)
74. Farde L., Ehrin E., Eriksson L., Greitz T., Hall H., Hedström C. G., Litton J. E., Sedvall G.. Substituted Benzamides as Ligands for Visualization of Dopamine Receptor Binding in the Human Brain by Positron Emission Tomography. Proc. Natl. Acad. Sci. U. S. A. 1985 ; 82: 3863-3867 (Pubitemid 15246452)
75. Gunn R. N., Murthy V., Catafau A. M., Searle G., Bullich S., Slifstein M., Ouellet D., Zamuner S., Herance R., Salinas C., et al. Translational Characterization of [11C]GSK931145, a PET Ligand for the Glycine Transporter Type 1. Synapse. 2011 ; 65: 1319-1332
76. DeLorenzo C., Kumar J. S. D., Mann J. J., Parsey R. V.. In Vivo Variation in Metabotropic Glutamate Receptor Subtype 5 Binding Using Positron Emission Tomography and [11C]ABP688. J. Cereb. Blood Flow Metab. 2011 ; 31: 2169-2180
77. Hietala J., Nyman M., Eskola O., Laakso A., Grönroos T., Oikonen V., Bergman J., Haaparanta M., Forsback S., Marjamäki P., et al. Visualization and Quantification of Neurokinin-1 (NK1) Receptors in the Human Brain. Mol. Imaging Biol. 2005 ; 7: 262-272
78. Burns H. D., Van Laere K., Sanabria-Bohórquez S., Hamill T. G., Bormans G., Eng W.-S., Gibson R., Ryan C., Connolly B., Patel S., et al. [18F]MK-9470, a Positron Emission Tomography (PET) Tracer for In Vivo Human PET Brain Imaging of the Cannabinoid-1 Receptor. Proc. Natl. Acad. Sci. U. S. A. 2007 ; 104: 9800-9805 (Pubitemid 47175347)
79. Pike V. W., McCarron J. A., Lammertsma A. A., Osman S., Hume S. P., Sargent P. A., Bench C. J., Cliffe I. A., Fletcher A., Grasby P. M.. Exquisite Delineation of 5-HT1A Receptors in Human Brain with PET and [carbonyl-11C]WAY- 100635. Eur. J. Pharmacol. 1996 ; 301: R5 - R7